

HIGH-THROUGHPUT ASSAYS FOR BIOTIN PROTEIN LIGASE : A NOVEL ANTIBIOTIC TARGET

by

Belinda Ng Ling Nah, BSc in Industrial Biology (Hons)

**A thesis submitted to the University of Adelaide in fulfillment of
the requirement for the degree of Master of Science**



**School of Molecular & Biomedical Science
The University of Adelaide
Adelaide, South Australia, 5005**

January 2009

TABLE OF CONTENTS

TABLE OF CONTENTS	i
ABSTRACT	iv
STATEMENT OF ORIGINALITY	vii
ACKNOWLEDGEMENTS	viii
LIST OF FIGURES	ix
LIST OF TABLES	x
LIST OF PUBLICATIONS	xi
LIST OF ABBREVIATION	xii
CHAPTER 1 INTRODUCTION	1
1.1 NEEDS FOR NEW ANTIBIOTICS	1
1.2 BIOTIN.....	2
1.3 BIOTIN-DEPENDENT ENZYMES	3
1.4 BIOTIN DOMAINS.....	4
1.5 BIOTIN PROTEIN LIGASE (BPL)	6
1.6 MICROBIAL BPLS	6
1.6.1 <i>Escherichia coli</i> BPL (BirA).....	7
1.6.2 <i>Pyrococcus horikoshii</i> BPL.....	9
1.7 EUKARYOTIC BPLS	10
1.8 AIMS AND SIGNIFICANCE	11
1.8.1 Project Aims.....	11
1.8.2 Project Significance.....	12
CHAPTER 2 GENERAL MATERIALS AND METHODS	13
2.1 MATERIALS	13
2.1.1 General Materials	13
2.1.2 Chemical Reagents.....	14
2.1.3 Bacterial Strains	15
2.1.4 Bacterial Media	15
2.1.5 Commercial Kits	15
2.1.6 Buffers and Solutions	16
2.1.7 Radiochemical.....	17
2.1.8 Peptide.....	17
2.1.9 Primers	18
2.1.10 Plasmid.....	19
2.1.11 Computer Software	19
2.1.12 Web Resources	19

2.2	GENERAL METHODS	20
2.2.1	Protein Techniques	20
2.2.1.1	Preparation of cell lysates	20
2.2.1.2	Determination of protein concentration	20
2.2.1.3	SDS-PAGE electrophoresis and gel staining.....	21
2.2.1.4	Western blot analysis.....	21
2.2.1.5	MALDI mass spectrometry	21
2.2.2	Molecular Biology Techniques	22
2.2.2.1	Agarose gel electrophoresis	22
2.2.2.2	Preparation of DH5- α competent cells.....	22
2.2.2.3	Preparation of chemically competent <i>E. coli</i>	23
2.2.2.4	Restriction Digest of DNA	23
2.2.2.5	Ligation of DNA fragments.....	24
2.2.2.6	Transformation of competent cells	24
2.2.2.7	Glycerol stocks	24
2.2.2.8	Purification of Plasmid DNA.....	24
2.2.2.9	Quantification of DNA.....	25
2.2.2.10	DNA sequencing	25
2.2.2.11	PCR Protocols.....	25
2.2.3	In-vitro ³ H-biotin biotinylation assay	26

CHAPTER 3 DEVELOPMENT AND CHARACTERIZATION OF A HIGH-THROUGHPUT ASSAY FOR *E. COLI* BPL 27

3.1	INTRODUCTION	27
3.2	SPECIFIC METHODS	29
3.2.1	Expression and purification of protein	29
3.2.1.1	<i>E. coli</i> BPL (<i>BirA</i>)	29
3.2.1.2	<i>E. coli</i> BCCP	31
3.2.2	BirA assay and fluorescence polarization	32
3.2.3	Peptide methods	33
3.2.4	Virtual screening for ATP analogues	33
3.2.5	Disc diffusion assay	34
3.2.6	Minimal inhibitory concentration (MIC) assay	34
3.3	RESULTS AND DISCUSSION.....	35
3.3.1	Principle of the assay.....	35
3.3.2	Peptide 85-11 is a suitable BirA substrate.....	36
3.3.3	Development of the assay.....	37
3.3.4	Kinetic analysis of BirA	38
3.3.5	Inhibition studies	39
3.3.6	Intra- and inter-assay variation.....	40
3.3.7	Compound screening for BirA inhibitors	41
3.3.7.1	ATP analogues.....	41
3.3.7.2	Biotinol-5'-AMP.....	44
3.4	CONCLUSION.....	45

CHAPTER 4	ASSAY ADAPTATION FOR <i>S. AUREUS</i> BPL	48
4.1	INTRODUCTION	48
4.2	SPECIFIC METHODS	49
4.2.1	Minimal inhibitory concentration assay (MIC)	49
4.2.2	Recombinant protein expression and purification	49
4.2.2.1	<i>SaBPL</i>	49
4.2.2.2	<i>Apo SaPC90</i>	51
4.2.3	Protein labeling with fluorescein-5'-maleimide	52
4.2.4	BPL Assay and Fluorescence Polarization	52
4.2.5	IC ₅₀ and K _i for biotin analogues	53
4.3	RESULTS AND DISCUSSION	53
4.3.1	DNA manipulations	53
4.3.2	Characterization of btnOH-AMP as an anti- <i>S. aureus</i> agent	54
4.3.3	Mechanism of inhibition of biotinol-5'-AMP	54
4.3.4	Principle of the assay	55
4.3.5	Identify substrate for <i>SaBPL</i>	55
4.3.6	Mutagenesis and protein labeling	57
4.3.7	Analysis of biotin domains as a BPL substrate	58
4.3.7.1	Analysis of fluorescein placement with holo-domains	58
4.3.7.2	Kinetic analysis of biotin domains	59
4.3.8	Development of the assay	60
4.3.9	Biological properties of <i>SaBPL</i>	61
4.3.10	Kinetic analysis of <i>SaBPL</i>	62
4.3.11	Inhibition studies	62
4.3.12	Intra- and inter-assay variation	63
4.3.13	Biotin analogues as inhibitors for <i>SaBPL</i>	64
4.4	CONCLUSION	66
CHAPTER 5	FINAL DISCUSSION AND FUTURE DIRECTIONS	68
5.1	BPL INHIBITORS AS A NEW CLASS OF ANTIBIOTIC	68
5.2	PROPOSED UPTAKE MECHANISM OF BIOTIN ANALOGUES	69
5.3	ASSAY MINIATURIZATION FOR HIGH-THROUGHPUT SCREENING	72
5.4	FUTURE DIRECTION	73
APPENDIX A	: DOUBLE RECIPROCAL LINEWEAVER-BURK PLOT	75
APPENDIX B	: PUBLISHED PAPER	76
REFERENCES		83

ABSTRACT

Antibiotics are defined as chemical substances that inhibit or limit the growth of microorganisms. Since the second world war, antibiotics have been widely used to reduce the morbidity and mortality associated with serious bacterial infections caused by organisms such as *Staphylococcus aureus*. However, it has become increasingly difficult to treat bacterial infections due to the emergence of antibiotic resistant strains. The first clinical case of drug resistant bacteria was observed in *S. aureus* in 1947, just four years after the mass production of penicillin. Since then, resistance has been reported to every antibiotic ever employed. According to the Centres for Disease Control and Prevention of the United States, more than 70% of hospital-acquired infections show resistance to at least one commonly used antibiotic. Coupled with the paucity of therapeutic agents in the pipeline, there is now an urgent demand for new antibiotics. One of the strategies employed to combat drug resistant bacteria requires new chemical entities that work through novel drug targets for which there is no pre-existing resistance. This thesis focuses on the essential metabolic enzyme biotin protein ligase (BPL) as one such new drug target.

BPL is the enzyme responsible for covalently attaching the cofactor biotin prosthetic group onto the biotin-dependent enzymes such as the carboxylases, decarboxylases and transcarboxylases. Enzymatic biotinylation proceeds via a two-step reaction whereby biotinyl-5'-AMP is synthesized from biotin and ATP before the biotin moiety is transferred onto the side chain of one specific lysine present in the active site of the biotin-dependent enzyme. One example of an important biotin-dependent enzyme is acetyl CoA carboxylase (ACC). ACC catalyzes the first committed step in fatty acid

biosynthesis. Through genetic studies, it has been demonstrated that BPL activity is essential for bacterial survival.

The aim for this project was to develop a convenient, high-throughput assay to measure BPL activity. This assay would permit 1) quantitative kinetic analysis of ligands and inhibitors and 2) screening of compound libraries for new BPL inhibitors. We propose that BPL inhibitors can be developed into new antibiotic agents. The novel BPL assay was developed employing fluorescence polarization (FP). FP is a light based technique which uses plane polarized light for the detection of tumbling motion of fluorescent molecules in solution. As polarization of the emitted light is relative to the apparent molecular mass of the fluorophore, this technique can be used for quantitation of changes in molecular mass of target molecules. This enabled 1) rapid kinetic analysis, 2) a minimal number of handling steps, 3) no washing steps and 4) automation by robotics.

A first generation assay was developed for *Escherichia coli* BPL using peptide 85-11 that has been shown to be a convenient substrate. Following the BPL reaction, biotinylated peptides will form large molecular mass complexes with avidin. The amount of product could then be quantitated using FP. Here, kinetic analysis of MgATP (K_m 0.25 ± 0.01 mM) and biotin (K_m 1.45 ± 0.15 μ M) binding produced results consistent with published data. We validated this assay with inhibition studies with end products of the BPL reaction, AMP and pyrophosphate, and a compound, biotinol-5'-AMP. Statistical analysis, performed upon both intraassay and interassay results ($n = 30$), showed the coefficient of variance to be <10% across all data sets. Furthermore, the Z' factors between 0.5 and 0.8 demonstrated the utility of this technology in high-throughput applications. However, the use of peptide 85-11, a substrate specific to *E. coli* BPL, does limit the application of this methodology to *E. coli*.

In the second generation FP assay, I adapted this technology for *S. aureus* BPL by employing the biotin domain of *S. aureus* pyruvate carboxylase. Insertion of a fluorescein label was achieved by first engineering a cysteine residue into the domain by site directed mutagenesis then incubation with fluorescein-5'-maleimide. A series of mutants was created to investigate optimal positioning of the label into the substrate. Furthermore, the minimal size of the functional domain was determined. Our data showed that the placement of the fluorescein label is an important aspect of this project. Using this approach, I identified that a 90 amino acid domain with the label at position 1134 was optimal. Kinetic analysis of ligand binding showed *SaBPL* had a K_m for biotin at $3.29 \pm 0.37 \mu\text{M}$ and K_m for MgATP at $66 \pm 16.08 \mu\text{M}$. This was in good agreement with data obtained from our previous assay measuring ^3H -biotin incorporation. Inhibitor studies with pyrophosphate and analogues of biotin and biotinyl-5'-AMP further validated the assay.

Various studies have shown cross-species biotinylation activities by a diverse range of BPLs. Therefore, using this methodology with a biotin domain as the substrate potentially provides a convenient assay for all BPLs.

STATEMENT OF ORIGINALITY

This thesis contains no material that has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material that has been previously published or written by another person, except where due reference has been made in the text.

I consent to this thesis, when deposited in the University library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

Belinda Ng Ling Nah

ACKNOWLEDGEMENTS

I would like to take this opportunity to express my deepest gratitude and appreciation to all the wonderful people who are directly and indirectly involved in the completion of this study:-

First of all, I would like to thank my supervisors, Assoc. Prof. Grant Booker and Dr. Steven Polyak for giving me the opportunity to participate in this research. Your dedication, priceless advice and time spent are very much appreciated. I humbly acknowledge the breadth of perspective and experience that I have gained, professionally and personally, under your guidance.

Thanks also to Prof. John Wallace who is always ready to impart his knowledge and experience. To all the past and present members of the BPL team – Assoc. Prof. Mathew Wilce (Monash University), Prof. Andrew Abell, Dr. Daniel Pedersen, Dr. Renato Morona, William, Kevin, Nicole, Lisa, Lingusa and Daniel – thank you for the helpful discussion and valuable advice on matters regarding BPL. Your efforts had contributed tremendously to the success of this work. Iain and Cvetan – really appreciate your help and advice pertaining *in-silico* screening and FP assay. To the other members of Booker Lab (Hui, Philippa, Ethan and John) and Wallace lab (Dr. Briony, Clair, Carlie, Shee Chee and Kerrie), thank you all for making this such an enjoyable journey for me. Your caring nature and friendship has made my time in Australia an experience that far surpassed my expectation, one of which I will never forget.

I would also like to acknowledge the Sarawak Government and Sarawak Biodiversity Centre for giving me this tremendous opportunity. Without their funding and support, it will be impossible for me to further my studies here in Adelaide.

Above all, my biggest thanks to my family especially *Papa* and *Mummy*. For as long as I remember, you are always there to provide me with all the support, encouragement and help I could ever ask for. Your unceasing love and care has shaped me to be the person I am today. “*Che*” and Hui, thanks for constantly keeping me in your prayer. Not forgetting a special thanks to Yew Zion. Thank you for your unyielding love, support, understanding and patience all this while. There is no word to express my gratitude for what you all have done for me.

Last but none the least, I would like to thank all my relatives and friends especially Michele and Mei Mei, and those I have failed to mention here. Your support, care and encouragement have kept me going when things are not going well. I am truly blessed to have you all as part of my life.

“Praise God for all His grace and blessings!”

LIST OF FIGURES

- Figure 1.1** : Comparison of sequence alignment of the biotin domains from various organisms
- Figure 1.2** : X-ray crystallography structure of holo *E. coli* BCCP-87 in ribbon presentation
- Figure 1.3** : Schematic diagram and equations of two-step biotinylation reaction
- Figure 1.4** : Crystal structure of BirA
- Figure 1.5** : Schematic diagram of the relative length and predicted catalytic domain of biotin protein ligases
- Figure 3.1** : Calibration curve for product formation
- Figure 3.2** : Kinetic analysis of ligand binding
- Figure 3.3** : Inhibition of BirA activity by MgAMP
- Figure 3.4** : Inhibition of BirA by pyrophosphate
- Figure 3.5** : ATP analogues for BirA
- Figure 3.6** : Inhibition of BirA by biotinol-5'-AMP
- Figure 3.7** : Sequence alignment of *E. coli* biotin domains and minimal peptide 85-11
- Figure 4.1** : Vector map for pGEX-4T-2 for mutagenesis study
- Figure 4.2** : Minimal inhibition concentration for btnOH-AMP
- Figure 4.3** : Concentration dependent inhibition of *Sa*BPL by btnOH-AMP and associated double-reciprocal Lineweaver-Burk plots
- Figure 4.4** : Deconvoluted mass spectra
- Figure 4.5** : Mutation sites on *Sa*PC90
- Figure 4.6** : Western blot of in-vivo biotinylation
- Figure 4.7** : FP with *Sa*PC biotin domain constructs
- Figure 4.8** : Expression and purification of *Sa*PC90 analysed by SDS-PAGE
- Figure 4.9** : Kinetic analysis of biotin domains
- Figure 4.10** : Calibration curve for product formation
- Figure 4.11** : Effect of removing reaction components on *Sa*BPL activity
- Figure 4.12** : Biological properties of *Sa*BPL
- Figure 4.13** : Kinetic analysis of ligand binding
- Figure 4.14** : Inhibition of *Sa*BPL activity by pyrophosphate (PPi)
- Figure 4.15** : Structures of *Sa*BPL inhibitors

LIST OF TABLES

Table 3.1 : Effect of removal of reaction components on BirA activity.....	38
Table 3.2 : Activity of E. coli BPL with various nucleotide triphosphates.....	39
Table 3.3 : Effect of DMSO on BirA activity.....	40
Table 3.4 : Statistical analysis of the BirA assay.....	41
Table 3.5 : Inhibition studies with ATP analogues.....	43
Table 4.1 : Activity of SaBPL with 5.5 mM of various metal ions.....	61
Table 4.2 : Effect of DMSO on SaBPL activity.....	63
Table 4.3 : Statistical analysis of the SaBPL assay.....	64
Table 4.4 : IC ₅₀ and K _i value for compounds tested.....	66

LIST OF PUBLICATIONS

Refereed journal :

Ng, B., Murchland, I., Abell, A. D., Wilce, M. C., Wallace, J. C., Polyak, S. W. and Booker, G. W. (2008) "Engineered biotin domains as fluorescent substrates for biotin protein ligase," *Analytical Biochemistry* - Submitted

Ng, B., Polyak, S. W., Bird, D., Bailey, L., Wallace, J. C. and Booker, G. W. (2008) "Escherichia coli biotin protein ligase: characterization and development of a high-throughput assay," *Analytical Biochemistry* 376 (1): 131-136

Conference abstracts :

Ng, B., Pardini N.R., Tieu W., Kuan K., Morona R., Abell A., Wilce M.C.J., Wallace J.C., Polyak S.W. and Booker G.W. (2008) Discovery of biotin protein ligase as a novel class of antibiotic. *University of Adelaide, School of Molecular and Biomedical Sciences Research Symposia* pos 12

Ng, B., Pardini N.R., Tieu W., Kuan K., Morona R., Abell A., Wilce M.C.J., Wallace J.C., Polyak S.W. and Booker G.W. (2008) Discovery of biotin protein ligase as a novel class of antibiotic. *ComBio2008* pos WED-024

Ng, B., Pardini, N., Tieu, W., Kuan, K., Morona, R., Wallace, J. C., Wilce, M., Abell, A., Booker, G. W. & Polyak, S. W. (2008) Inhibitor of biotin protein ligase: a novel class of antibiotics for the treatment of *Staphylococcus aureus*. *Australian Society for Medical Research SA division Scientific Meeting*

Ng, B., Bird, D., Wallace, J. C., Booker, G. W. & Polyak, S. W. (2008) *Escherichia coli* biotin protein ligase: Development and validation of a high throughput assay. *Australian Society for Medical Research SA division Scientific Meeting* pos 11

Ng, B., Bird, D., Wallace, J. C., Booker, G. W. & Polyak, S. W. (2008) *Escherichia coli* biotin protein ligase: Development and validation of a high throughput assay. *Proc. Lorne Conference on Protein Structure and Function* pos 362

Ng, B., Bird, D., Wallace, J. C., Booker, G. W. & Polyak, S. W. (2007) Biotin protein ligase: A novel antibiotic target. *South Australian Division AUSBIOTECH Students Association Student Awards*. **Finalist

Ng, B., Bird, D., Wallace, J. C., Booker, G. W. & Polyak, S. W. (2007) *Escherichia coli* biotin protein ligase: Development and validation of a high throughput assay. *University of Adelaide, School of Molecular and Biomedical Sciences Research Symposia*.

LIST OF ABBREVIATION

ACC	acetyl CoA carboxylase
Amp	ampicillin
AMP	adenosine monophosphate
Amp ^R	ampicillin resistant
ATP	adenosine triphosphate
BCA	bicinchoninic acid
BCCP	biotin carboxyl carrier protein
BirA	biotin inducible repressor A
BLAST	basic local alignment search tool
BME	β-mercaptoethanol
bp	base pair
BPL	biotin protein ligase
BSA	bovine serum albumin
BtnOH-AMP	biotinol-5'-AMP
°C	degree Celsius
C-	carboxyl-
CaCl ₂	calcium chloride
Cpd	compound
CTP	cytidine triphosphate
cv	column volume
CV	coefficient of variation
DMSO	dimethyl sulfoxide
DNA	deoxynucleotide triphosphate
dNTPs	deoxynucleotide triphosphates
DTT	dithiothreitol
ECL	enhanced chemiluminescence
EDTA	ethylene diamine tetra-acetic acid
Fl-	fluorescently labeled
FP	fluorescence polarization
FPLC	fast protein liquid chromatography

GST	glutathione-S-transferase
GTP	guanosine triphosphate
HCl	hydrochloric acid
HEPES	4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid
hr	hour
HRP	horseradish peroxidase
IC ₅₀	inhibition concentration at 50% activity
Int	intensity
IPTG	isopropyl β-D-1-thiogalactopyranoside
ITP	inosine triphosphate
kb	kilobase pair
KCl	potassium chloride
kDa	kilo dalton
K_i	inhibition constant
K_M	Michaelis-Menten constant
KPO ₄	potassium phosphate
LB	luria broth
m	metre
μ	micron
M	molar
mA	milliampere
Mg	magnesium
MIC	minimal inhibitory concentration
Min	minute, minutes
Mn	manganese
MOPS	3-morpholinopropanesulfonic acid
MS	mass spectrometry
MW	molecular weight
MWCO	molecular weight cut-off
n	nano
N-	amino-
NMR	nuclear magnetic resonance
OD _x nm	optical density at x nm wavelength
p	pico

P	polarization unit
PBS	phosphate buffered saline
PC	pyruvate carboxylase
PCR	polymerase chain reaction
PDB	protein data bank
<i>PhBPL</i>	<i>Pyrococcus horikoshii</i> biotin protein ligase
PMSF	phenylmethylsulfonylfluoride
PVDF	polyvinyl difluoride
RNA	ribonucleic acid
rpm	revolutions per minute
RT	room temperature
<i>SaBPL</i>	<i>S. aureus</i> biotin protein ligase
<i>SaPC</i>	<i>S. aureus</i> pyruvate carboxylase biotin domain
SDS	sodium dodecyl sulphate
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
sec	second
SEM	standard error of the mean
Std. dev.	standard deviation
TBS	tris buffered saline
TBS-T	tris buffered saline and 0.1% (v/v) Tween-20
TEMED	N,N,N,N'-tetramethylethylene-diamine
Tris	2-amino-2-hydroxymethylpropane-1,3-diol
TTP	thymidine triphosphate
Tween-20	polyoxyethylene-sorbitan monolaurate
U	units (active)
UTP	uridine triphosphate
UV	ultra violet
V _{max}	maximum velocity
WB	Western blot
WT	wild type
yBPL	yeast (<i>S. cerevisiae</i>) biotin protein ligase
ΔmP	milli polarization unit difference between apo and holo substrate